Additional file 2: of Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial

Exploratory analysis – speed of healing over 6 weeks by assessment method. Table showing results of exploratory analysis; speed of healing over 6 weeks by assessment method. (DOCX 12 kb

Additional file 1: of Investigating the effect of independent, blinded digital image assessment on the STOP GAP trial

Agreement between unblinded measurements and trial measurements with outliers removed. Table showing agreement between unblinded measurements and trial measurements with outliers removed. (DOCX 12 kb

Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis

Aim: To compare the efficacy and tolerability of sodium-glucose co-transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adults with type 2 diabetes.Materials and methods: Electronic databases were searched from inception to 24th April 2019 for randomised controlled trials reporting change in glycated haemoglobin (HbA1c) at approximately 24 and/or 52 weeks for SGLT-2is and/or GLP-1RAs (classified as short- and long-acting). Bayesian network meta-analyses were conducted to compare within and between SGLT-2i and GLP-1RA classes for cardiometabolic efficacy and adverse events (PROSPERO registration number: CRD42018091306). Results: 64 trials (53 trials of 24 weeks; 7 trials of 52 weeks; 4 trials of both 24 and 52 weeks), comprising of 31,384 participants were identified. Compared to placebo, all treatments improved HbA1c. Long-acting GLP-1RAs reduced HbA1c compared to short-acting GLP-1RAs and SGLT-2 is, with semaglutide showing greater reduction compared to placebo (24 weeks: -1.49% (95% credible interval [CrI]: -1.76, -1.22), 52 weeks: -1.38% (-2.05, -0.71)) and all other treatments. Long-acting GLP-1RAs showed benefits in body weight and waist circumference reduction, while SGLT-2 is reduced blood pressure. SGLT-2is showed increased odds of genital infection in comparison to long-acting GLP-1RAs (odds ratio (95% CrI): 5.26 (1.45, 25.00)), while GLP-1RAs showed increased odds of diarrhoea in comparison to SGLT-2is (short-acting GLP-1RAs: 1.65 (1.09, 2.49), long-acting GLP-1RAs: 2.23 (1.51, 3.28)). No other differences were found between SGLT-2is and GLP-1RAs in adverse events. Conclusion: Long-acting GLP-1RAs showed superiority in reducing HbA1c levels, body weight and waist circumference. SGLT-2 is showed reductions in blood pressure levels. This review provide essential evidence to guide treatment recommendations in the management of type 2 diabetes<br